📰 Technology Applications Shared Resource News
Technology Applications Shared Resource News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Technology Applications Shared Resource. Real-time updates on events, politics, business and more.
October 6, 2023
Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and expands the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment this patient population.
September 21, 2023
Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
June 5, 2023
Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.
June 4, 2023
Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.